Vivek Subbiah: Future framework for Tissue agnostic drug development

Vivek Subbiah shared a post on LinkedIn:

“Hot off the press, Presenting to the world a future framework for Tissue agnostic drug development – Our Special article published ESMO – European Society for Medical Oncology

flagship journal Annals of Oncology Annals of Oncology
– A major milestone in Tissue Agnostic Precision Medicine marks the start of what we hope is the future of tissue agnostic drug development,

“The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development”

The European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) coordinated a project to optimise tumour-agnostic drug development. Represents an amazing body of insightful work by amazing colleagues – Benedikt Westphalen et al
Huge shout out to Diogo Martins Branco & special thanks to George Pentheroudakis
CMO ESMO to help us get to the finish line, Fabrice Andre for the support & Svetlana Jezdic for her exceptional efforts in keeping us on track.

Delighted to share this as part of a SPECIAL ESMO & American Society of Clinical Oncology (ASCO) joint session in Barcelona, Spain – “Tumour-agnostic drug development” at the ESMO congress 2024 – session chaired by both ASCO & ESMO Presidents ESMO24 OncoAlert
Sarah Cannon Research Institute The US Oncology Network SCRI Oncology Partners

Thank you Diogo Martins Branco, George Pentheroudakis, Juliana Rodrigues Beal, Claudia Cardone, Alison Schram, Giuseppe Curigliano, Shivaani Kummar, Razelle Kurzrock, Sewanti Limaye, MBBS, MD, MS Joaquin Mateo, Juliana Rodrigues, Beal Claudia, Cardone Niamh, Coleman Alison, Schram Susan, Halabi Stefan, Michiels Christina ,Yap fabrice andre Frédéric, Bibeau Giuseppe, Curigliano Elena, Garralda Cabanas, Shivaani Kummar, Razelle Kurzrock, Prof. Sonja Loges MD, PhD ,Aurélien Marabelle, Caterina Marchio, Joaquin Mateo, Jordi Rodón, Tanja Spanic.

10:15 – 11:45
Oviedo Auditorium – Hall 3
When : Sun, 15.09.2024
Link”

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Authors: C B Westphalen, D Martins-Branco, J R Beal, C Cardone, N Coleman, A M Schram, S Halabi, S Michiels, C Yap, F André, F Bibeau, G Curigliano, E Garralda, S Kummar, R Kurzrock, S Limaye, S Loges, A Marabelle, C Marchió, J Mateo, J Rodon, T Spanic, G Pentheroudakis, and V Subbiah.

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.